More News! For those who want to keep up with everything

More News! 8 Nov 2022

ISA Pharmaceuticals’ Amplivant adjuvant boosts immune response in SLP immunotherapy

ISA Pharmaceuticals B.V, a Netherlands-based clinical stage biotech developing immunotherapies to treat cancers and infectious diseases has had a phase 1 clinical study published. The study, using ISA Pharmaceuticals’ Amplivant adjuvant and synthetic long peptide (SLP) therapeutic vaccine technology was published by Leiden University Medical Centre (LUMC) in the Journal for ImmunoTherapy for Cancer. It […]

November 8, 2022 - 2 minutesmins - By Liza Laws

More News! 7 Nov 2022

Sensorion granted rare pediatric disease designation by FDA for lead therapy gene

Sensorion has announced that the US Food and Drug Administration (FDA) has granted rare pediatric disease designation to its lead therapy gene candidate, OTOF-GT. The gene therapy is intended for the treatment of otoferlin gene mediated hearing loss. Sensorion’s OTOF-GT gene therapy development program aims to restore hearing in people living with otoferlin deficiency, one […]

November 7, 2022 - 2 minutesmins - By Liza Laws

More News! 4 Nov 2022

Sanofi and AstraZeneca drug, Beyfortus, for RSV in babies and children approved

A drug being developed jointly by Sanofi and AstraZeneca for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants was approved today (November 4). The European Commission has approved Beyfortus which is so far the first and only broadly protective option against the virus. Thomas Triomphe, executive vice president, […]

November 4, 2022 - 2 minutesmins - By Liza Laws

More News! 4 Nov 2022

Optibrium and Lhasa Limited study published on predictive modelling for enzymes

A peer reviewed study published in the Journal of Medicinal Chemistry has been published by Optibrium and Lhasa Limited that shows advance predictive modelling for drug-metabolizing enzymes. The companies are two of the leading developers of software and artificial intelligence (AI) solutions for drug discovery and development. In the paper, ‘Predicting Regioselectivity of AO, CYP, […]

November 4, 2022 - 3 minutesmins - By Liza Laws

More News! 4 Nov 2022

Alimentiv and Summit collaborate to tackle liver disease NASH

Drug development programs will be driven forward by a collaboration between Alimentiv Inc. and Summit Clinical Research, in a bid to tackle non-alcoholic steatohepatitis (NASH). They announced a strategic alliance to tackle the now growing global epidemic with no approved treatments. It says that current challenges include optimizing and end-point assessment, minimizing screen failures and […]

November 4, 2022 - 3 minutesmins - By Liza Laws

More News! 31 Oct 2022

New drug application for chronic kidney disease sparks $35M milestone payment

A submission has been made for a new drug application by Japanese Kyowa Kirin Co. Ltd. for the improvement of hyperphosphatemia in patients with chronic kidney disease (CKD). The company has submitted the application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for tenapanor, which helps those with CKD on dialysis. Ardelyx, Inc. […]

October 31, 2022 - 3 minutesmins - By Liza Laws

More News! 31 Oct 2022

Drug discovery company signs exclusive license to use university’s technology

A drug discovery and development company using deubiquitylase (DUB) modulators as therapeutics for areas of high unmet needs has signed an exclusive license with the University of Southern Denmark for its UbiSite technology. Sheelagh Frame, is chief scientific officer, at Ubiquigent, the company that has signed the agreement. She said: “We are delighted to have […]

October 31, 2022 - 3 minutesmins - By Liza Laws

More News! 28 Oct 2022

‘Dark matter’ creates a whole new level of cancer gene activity in tumors, researchers say

A whole new level of control of cancer gene activity within tumors, has been described by researchers as ‘dark matter’. It was recently discovered and published in two major studies at the same time in Nature that cancers can evolve to become more aggressive without relying on DNA mutations. Testing cancers for just the DNA […]

October 28, 2022 - 6 minutesmins - By Liza Laws

More News! 26 Oct 2022

Study shows ability to develop and apply targeted treatment in head and neck cancers

A joint study looked at the development identification of specific markers to improve risk assessment of patients with difficult to treat head and neck tumors. Malignant tumors in these areas are very heterogeneous and have a lack of prognostic markers – a significant impediment to personalized treatment. The joint study by MedUni Vienna and the […]

October 26, 2022 - 3 minutesmins - By Liza Laws

More News! 26 Oct 2022

Neuraxpharm to commercialize device giving early warning of epileptic seizures

A wearable medical device that can give an early warning of an epileptic seizure has been developed by medical device startup, mjn-neuro. Central nervous system (CNS) specialist Neuraxpharm Group entered the digital health market by signing a commercialization agreement with the developer for mjn-SERAS with exclusivity in Europe. With this agreement, Neuraxpharm increases its end-to-end […]

October 26, 2022 - 4 minutesmins - By Liza Laws

More News! 25 Oct 2022

Watch: NLS Days NLSInvest award winners – Asgard Therapeutics

The two biotech start-up companies MyoPax and Asgard Therapeutics won first and second prize at NLSINvest Awards, out of 40 companies that participated in Nordic Life Science Days’ start-up pitching challenge. 40 selected Nordic start-up companies attended Nordic Life Science Days, the largest partnering conference for life sciences in the Nordics, which was held in […]

October 25, 2022 - 2 minutesmins - By Jim Cornall

More News! 24 Oct 2022

Sensorion gets go-ahead from France for trial of drug to prevent hearing loss

Biotech company, Sensorion, today (October 24) announced that the initiation of a proof of concept (PoC) clinical trial of SENS-401 (Arazasetron) in patients with Cisplatin-Induced Ototoxicity (CIO) has been approved by the regulatory authorities in France. Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies […]

October 24, 2022 - 3 minutesmins - By Liza Laws

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

More News!

ISA Pharmaceuticals’ Amplivant adjuvant boosts immune response in SLP immunotherapy

Sensorion granted rare pediatric disease designation by FDA for lead therapy gene

Sanofi and AstraZeneca drug, Beyfortus, for RSV in babies and children approved

Optibrium and Lhasa Limited study published on predictive modelling for enzymes

Alimentiv and Summit collaborate to tackle liver disease NASH

New drug application for chronic kidney disease sparks $35M milestone payment

Drug discovery company signs exclusive license to use university’s technology

‘Dark matter’ creates a whole new level of cancer gene activity in tumors, researchers say

Study shows ability to develop and apply targeted treatment in head and neck cancers

Neuraxpharm to commercialize device giving early warning of epileptic seizures

Watch: NLS Days NLSInvest award winners – Asgard Therapeutics

Sensorion gets go-ahead from France for trial of drug to prevent hearing loss

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!